AngioDynamics

What AngioDynamics does

AngioDynamics (NASDAQ: ANGO) is a publicly traded medical device company founded in 1988 and headquartered in Latham, New York. The company designs, manufactures, and sells medical devices for minimally invasive, image-guided vascular and oncology procedures, organized into two reporting segments. The Med Tech segment (47-48% of FY2026 revenue) comprises higher-growth platforms: the NanoKnife System using irreversible electroporation (IRE) for soft tissue ablation, including prostate cancer; the Auryon peripheral atherectomy system; the AlphaVac mechanical thrombectomy system for pulmonary embolism; and the Solero microwave ablation system. The Med Device segment (legacy) includes the VenaCure EVLT laser varicose vein system, the AngioVac venous drainage cannula, and implantable port families (SmartPort CT, BioFlo, Vortex, Xcela Plus) for chemotherapy access.

AngioDynamics operates a hybrid go-to-market combining approximately 100 direct sales representatives in North America with regional distribution managers covering APAC (Hong Kong, Taiwan, Vietnam, Thailand, India, Australia, New Zealand) and Brazil. The company sells to acute care hospitals, academic medical centers, integrated health systems, interventional radiology/cardiology practices, and specialty clinics across more than 15 countries. Revenue is generated through capital equipment sales (laser consoles, NanoKnife generators) and recurring consumable sales (electrodes, catheters, procedure kits), with quote-based pricing to healthcare institutions. FY2026 net sales were $320.2M (up 9.4% year-over-year) and the company is debt-free with $53.9M cash and ~89% institutional ownership.

The company is undergoing a strategic transformation toward its higher-growth Med Tech portfolio, having divested its PICC/midline catheter business to Spectrum Vascular and its BioSentry line to Merit Medical Systems for $100M. Key catalysts include the December 2024 FDA 510(k) clearance for NanoKnife prostate tissue ablation, the Medicare LCD for NanoKnife IRE effective July 2026, and expanded European indications across liver, kidney, pancreas, and prostate. Concurrent leadership transitions include announced retirements of CEO Jim Clemmer and CFO Steve Trowbridge during fiscal 2027.

Name

AngioDynamics

Legal name

AngioDynamics, Inc.

Website

https://angiodynamics.com

Company type

Public

Founded year

1988

Operating status

Operating

Headcount range

501–1,000 employees

Short description

AngioDynamics is a publicly traded medical device company that designs, manufactures, and sells minimally invasive vascular and oncology devices—including the NanoKnife IRE ablation system, Auryon atherectomy platform, AlphaVac thrombectomy system, and implantable ports—to hospitals, health systems, and interventional specialty practices globally.

Ownership category

akta.pro rank

NAICS

Surgical and Medical Instrument Manufacturing (339112), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical Appliance and Supplies Manufacturing (339113), Medical Equipment and Supplies Manufacturing (3391)

SIC

Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)

akta.pro primary industry

Interventional Radiology & Image-Guided Therapy Systems (HLAHABAG)

akta.pro secondary industries

Open & Minimally Invasive Surgical Instruments (Handheld, Laparoscopic, MIS) (HLAHADAA), Surgical Navigation, Tracking & Intraoperative Guidance (Ortho/Neuro/ENT) (HLAHADAG), Endoscopic Therapeutic & Access Devices (Trocars, dilators, biopsy/ablation tools) (HLAHADAN)

Keywords

• Medical devices
• Interventional oncology
• Vascular therapies
• Peripheral atherectomy
• Thrombectomy systems

Headquarters

HQ city

Latham

HQ country

United States

HQ region

North America

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Medical Device Sales: AngioDynamics generates revenue through the sale of medical devices and systems including the NanoKnife System, Auryon System, AlphaVac System, AngioVac System, VenaCure EVLT, and various port products. Revenue is derived from both capital equipment sales (laser consoles) and recurring consumable sales (electrodes, catheters, procedure kits).
2. Med Tech Segment: Higher-growth segment including NanoKnife, Auryon, and AlphaVac products. This segment represented 47% of total revenue in Q4 FY2026 and is projected to grow 12-15% in FY2027.
3. Med Device Segment: Legacy medical device segment including ports, introducers, and other vascular access products. This segment is expected to remain flat in FY2027.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels5 records

Core offering

AngioDynamics designs, manufactures, and sells minimally invasive, image-guided medical devices used in vascular and interventional oncology procedures. The portfolio spans two segments: Med Tech (NanoKnife IRE ablation, Auryon peripheral atherectomy, AlphaVac mechanical thrombectomy) and Med Device (VenaCure EVLT varicose vein ablation, AngioVac venous drainage, implantable port families including SmartPort CT, BioFlo, Vortex and Xcela Plus, plus drainage and angiographic catheters). Revenue is generated from both capital equipment sales (laser and IRE consoles) and recurring consumable sales (electrodes, catheters, procedure kits).

Product overview

AngioDynamics is a medical technology company offering a diversified portfolio of vascular and oncology medical devices. The product portfolio consists of two main segments: Med Tech (higher-growth platforms) including NanoKnife System (irreversible electroporation for soft tissue ablation and prostate cancer), AlphaVac System (mechanical thrombectomy for pulmonary embolism), Auryon System (peripheral atherectomy), and Solero Microwave Tissue Ablation; and Med Device (legacy products) including the VenaCure EVLT System (endovenous laser ablation for varicose veins), implantable port families (SmartPort CT, BioFlo, Vortex, Xcela Plus), AngioVac System (venous drainage), Habib 4X surgical devices, drainage catheters, angiographic catheters, guidewires, and various procedural accessories. The company is strategically shifting toward its Med Tech segment which now represents approximately 47-48% of total revenue.

Differentiator

Problem solved

Functional benefit

Brands

• NanoKnife: Irreversible electroporation system for soft tissue ablation including prostate cancer treatment
• Auryon
• AlphaVac
• AngioVac
• SmartPort
• Vortex
• BioFlo
• VenaCure EVLT
• Solero
• Habib 4X

Quantifiable outcome

• NanoKnife 24-month PRESERVE trial showed 94.4% follow-up completion with zero new treatment failures between 12 and 24 months, and 97% of patients with PSA below baseline
• +4 more outcomes

Named customers1 record

Segments4 records

Ideal customer profiles2 records

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Five partnerships are on record, tiered core and minor.

• University of ManchestercoreStrategic or Co-development Partner · 19 February 2026AngioDynamics announced the LIVER-IRE Global Registry in partnership with Professor Ajith Siriwardena at the University of Manchester to prospectively assess outcomes in patients receiving IRE treatment for liver tumors. This registry supports clinical adoption and real-world evidence development for multi-organ applications of the NanoKnife system.
• PERT ConsortiumcoreStrategic or Co-development Partner · 5 February 2026AngioDynamics and The PERT Consortium launched the ALPHA-PE Research Fund, an investigator-led initiative supporting independent pulmonary embolism research. The fund will distribute awards ranging from $50,000 to $750,000 over one to three years to both established and emerging investigators pursuing data-driven research focused on patient outcomes, workflow optimization, or novel therapeutic approaches.
• University College London HospitalcoreStrategic or Co-development Partner · 1 October 2025Partnership with University College London Hospital for a prospective registry study on prostate cancer treatment using the NanoKnife System, building clinical evidence for IRE technology in oncology applications.
• Palmetto GBAcoreOthers · 1 June 2025Palmetto GBA issued a final Local Coverage Determination (LCD L40205) establishing Medicare coverage for irreversible electroporation (IRE) delivered by AngioDynamics' NanoKnife System, effective July 5, 2026, for favorable intermediate-risk prostate cancer and metastatic colorectal cancer to the liver.
• Spectrum VascularminorChannel Partner/ Reseller/ Distributor · 1 February 2024AngioDynamics completed the sale of its PICC and midline catheter product portfolios to Spectrum Vascular. Spectrum Vascular was formed through the acquisition of vascular access businesses from Cook Medical and AngioDynamics, with Ken Miller as CEO and Doug Shook as CCO leading the company.

Scale indicators14 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Penumbra: Penumbra develops mechanical thrombectomy systems (Indigo, Lightning) for peripheral and neurovascular indications, including pulmonary embolism. It is the most direct competitor to AngioDynamics' AlphaVac and AngioVac in the mechanical thrombectomy space.
• Inari Medical: Inari Medical (acquired by Stryker) is a leading mechanical thrombectomy company with FlowTriever for pulmonary embolism and ClotTriever for deep vein thrombosis — directly competing with AlphaVac and AngioVac in the PE/DVT market.
• Shockwave Medical: Shockwave Medical (acquired by Johnson & Johnson) manufactures intravascular lithotripsy (IVL) for peripheral and coronary artery disease, directly competing with AngioDynamics' Auryon laser atherectomy system in the peripheral arterial disease treatment market.

Broad incumbents

• Boston Scientific: Boston Scientific is a large diversified medical device incumbent with overlapping portfolios in interventional cardiology, peripheral vascular (Eluvia, Ranger drug-coated balloons), and oncology — competing across multiple AngioDynamics franchises including Auryon, ports, and oncology ablation.
• Medtronic: Medtronic is a global medical device leader with extensive peripheral vascular (IN.PACT Admiral DCB), oncology, and vascular access portfolios. It competes with AngioDynamics in ports, peripheral atherectomy, and tissue ablation across most geographies.
• Abbott: Abbott's vascular franchise (formerly Abbott Vascular, including the acquired Cardiovascular Systems) competes in peripheral intervention, while Abbott's broader medical device business overlaps in oncology and vascular access — making it a broad incumbent competitor.
• BD (Becton Dickinson): BD has a substantial vascular access and ports portfolio (PowerPort, Groshong) that competes directly with AngioDynamics' SmartPort, BioFlo, Vortex, and Xcela Plus port families, alongside broader medical device offerings in peripheral intervention.
• Stryker: Stryker is a diversified medical device incumbent with overlapping neurovascular and vascular intervention capabilities, including the recently acquired Inari Medical mechanical thrombectomy franchise that competes with AngioDynamics' AlphaVac.

Regional players

• Edwards Lifesciences: Edwards Lifesciences is a structural heart and critical care leader with peripheral vascular and critical care monitoring adjacencies, partially overlapping with AngioDynamics' vascular portfolio in selected hospital channels.

Emerging players

• Cardiovascular Systems (CSI): Cardiovascular Systems (acquired by Abbott in 2023) developed orbital atherectomy systems for peripheral and coronary artery disease, a direct technology competitor to AngioDynamics' Auryon laser atherectomy platform in the peripheral intervention market.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/angiodynamics
• Xx.com/angiodynamics

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A6 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AngioDynamics